ReviewReviews in endocrine & metabolic disorders2026
Beyond weight: a stigma-free, integrated approach to obesity in patients affected by cancer.
Review in Reviews in endocrine & metabolic disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundObesity affects a substantial proportion of patients receiving cancer treatment and shapes prognosis, treatment tolerance, and survivorship outcomes. The longstanding reliance on body mass index has shaped a weight-centric paradigm that misses the metabolic and functional phenotypes behind clinical risk, and too often delivers care driven by weight stigma rather than by physiology.
objectivesThis framework paper reconsiders the management of obesity in patients affected by cancer along three interconnected lines: assessment beyond BMI, stigma-free communication, and integrated, phase-sensitive care along the cancer continuum. Key content. Body composition phenotyping, including the recognition of sarcopenic obesity, ectopic fat deposition, and myosteatosis, is now within reach through opportunistic radiomics on staging computed tomography, and yields prognostic information that BMI alone cannot deliver. International consensus statements increasingly frame obesity as a chronic, complex, and relapsing disease rather than a matter of individual responsibility, and emphasize that person-first language and the active reduction of weight bias should be embedded as core components of cancer care. The therapeutic armamentarium spans nutritional strategies grounded in ESPEN principles, structured exercise with resistance training at its core, behavioural and psychological support, GLP-1 receptor agonists, and metabolic-bariatric surgery, the latter linked to substantial reductions in cancer incidence and mortality. Goals shift along the continuum: lean mass optimisation in prehabilitation, lean mass preservation during active treatment, fat mass reduction in follow-up, and cachexia prevention in palliative phases.
conclusionsA phase-sensitive, multidisciplinary, stigma-free framework moves obesity care away from a weight-centric paradigm and toward optimisation of body composition and metabolic health throughout the cancer trajectory.
Indexed as
Identifiers
42611363What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.